drugset / Trial / NCT02587572

Safety and Efficacy Trial Using Allogeneic Human Mesenchymal Stem Cells: The SIRONA Trial

NCT02587572

Phase 2 Withdrawn Longeveron Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a phase 2b, randomized, placebo-controlled clinical trial designed to evaluate the safety and efficacy of Longeveron Mesenchymal Stem Cells (LMSCs) in subjects with metabolic syndrome and to assess the effects of LMSCs on endothelial function using several different doses.

Timeline

Start
2023-12-01
Primary completion
2023-12
Completion
2023-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Mesenchymal stem cell Cell therapy 10 cells Intravenous
Subject Mesenchymal stem cell Cell therapy 20 cells Intravenous
Subject Mesenchymal stem cell Cell therapy 100 cells Intravenous

Indications